A Closer Look Into the Role of Compounding Pharmacies

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

The installation of the new vial, syringe, and cartridge line is expected to take place throughout the coming year.

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands patient access in the process.